徐东平.乙型肝炎病毒的病毒学特点及其临床意义[J].解放军 医学杂志,2009, 34(6): 655-657. [2] Staschke KA, Colacino JM. Drug discovery and development of anti- viral agents for the treatment of chronic hepatitis B virus infection[J]. Prog Drug Res, 2001, Spec NO: 111-183. [3] Zoulim F. Detection of hepatitis B virus resistance to antivirals[J]. J Clin Virol, 2001, 21(3): 243-253. [4]徐东平,周先志.核苷(酸)类似物治疗慢性乙型肝炎耐药研究进 展[J].传染病信息,2007, 20(2): 68-70. [5]倪宏,骆抗先,刘定燮,等.乙型肝炎病毒全基因组真核表达质粒 的构建[J].第一军医大学学报,2001, 21(3): 185-186. [6]唐霓,黄爱龙,张秉强,等. 1.3倍乙型肝炎病毒全基因真核表达 载体的构建及在HepG2细胞中的表达[J].中华肝脏病杂志, 2003, 11(8): 464-466. [7]李文鹏,李彤,闫玲,等. 1.2倍基因组长度C基因型乙型肝炎病 毒重组体构建及其在HepG2细胞中表达和复制[J].肝脏,2008, 6(13): 211-215. [8] Chin R, Shaw T, Torresi J, et al . In vitro susceptibilities of wild- type or drug-resistant hepatitis B virus to(-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil[J]. An- timicrob Agents Chemother, 2001, 45(9): 2495-2501. [9] Durantel D, Carrouée-Durantel S, Werle-Lapostdle B, et al . A new strategy for studying in vitro drug susceptibility of clinical isolates of Human hepatitis B virus[J]. Hepatology, 2004, 40(4): 855-864 [10]纪冬,刘妍,王耀,等.慢性乙型肝炎患者血清HBV全长序列分析 及复制力评价.解放军医学杂志,2009, 34(6): 670-674.